Paper Details

  1. Home
  2. Paper Details

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.

Author: BaraliakosXenofon, DeodharAtul, DinaOluwaseyi, FallonLara, FleishakerDona, GenslerLianne S, KanikKeith S, MenonSujatha, Sliwinska-StanczykPaula, WangCunshan, WangLisy, WuJoseph, XuHuji, van der HeijdeDésirée

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tofacitinib demonstrated significantly greater efficacy than placebo in adults with active ankylosing spondylitis. No new potential safety risks were identified.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). METHODS: This phase III, randomised, double-blind, placebo-controlled study enrolled patients aged ≥18 years diagnosed with active AS, meeting the modified New York criteria, with cent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292568/

データ提供：米国国立医学図書館（NLM）

Tofacitinib: A New Hope for Ankylosing Spondylitis?

The world of rheumatology is always on the lookout for new and effective treatments for inflammatory conditions like ankylosing spondylitis (AS). This study delves into the efficacy and safety of tofacitinib, a medication that targets the immune system, in treating AS. The researchers used a rigorous double-blind, placebo-controlled trial design, a bit like hiding treasure in the desert and seeing who can find it. This ensures that the results are truly due to the medication and not just wishful thinking.

They found that tofacitinib was significantly more effective than a placebo in reducing AS symptoms. Imagine a camel caravan traversing a harsh desert; tofacitinib helped to smooth out the bumps and make the journey more comfortable.

Tofacitinib: A Promising Solution for Ankylosing Spondylitis

The results of this study are very encouraging for patients with AS. The researchers found that tofacitinib significantly improved the symptoms of AS in 56.4% of patients compared to 29.4% of those who received a placebo. It's like discovering a hidden oasis in the middle of the desert; a place of relief and healing.

Living with Ankylosing Spondylitis: What to Keep in Mind

While tofacitinib offers a new hope for AS patients, it's crucial to remember that every individual is different. As with any medication, it's important to discuss any concerns or potential side effects with your doctor. Keeping an open line of communication is like having a reliable camel guide who can help you navigate any challenges you may encounter along the way.

Dr. Camel's Conclusion

This study offers a glimmer of hope for people struggling with AS. Tofacitinib could be a valuable tool for managing the disease and improving quality of life. While further research is always needed, this study provides a significant step forward in the fight against this chronic inflammatory condition.

Date :
  1. Date Completed 2022-06-27
  2. Date Revised 2022-07-05
Further Info :

Pubmed ID

33906853

DOI: Digital Object Identifier

PMC8292568

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.